moderna_norwood_plant

Switzerland approves Moderna’s COVID-19 vaccine

pharmafile | January 13, 2021 | News story | Research and Development COVID-19, Moderna, Vaccine 

Moderna has announced that its COVID-19 vaccine has been authorised for use on those aged 18 or older in Switzerland.

The authorisation was given by Swissmedic, the Swiss Agency for Therapeutic Products, and was based on a rolling submission of data and the totality of scientific evidence shared by the company, including a data analysis from the pivotal Phase III clinical study announced on November 30. Swissmedic’s approval was also influenced by a recommendation from the Human Medicines Expert Committee, which has authorised the company’s vaccine for use.

The Swiss Federal Government has secured 7.5 million doses of the Moderna jab, and the first deliveries are expected to begin in Switzerland in the next week.

Moderna’s vaccine has also received authorisation from regulatory authorities in the US, Canada, Israel, the EU, and the UK. Additional authorisations are currently under review in other countries and by the WHO.

Stéphane Bancel, Chief Executive Officer of Moderna, said: “Having our COVID-19 vaccine authorised in Switzerland is an important milestone for us.

“Switzerland has played a critical role in Moderna’s history since our early days and it means a lot to us that we can now provide a highly effective vaccine to help protect the citizens of Switzerland.”

Darcy Jimenez

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

Merck and Moderna initiate phase 3 study of NSCLC treatment

Merck (known as MSD outside of the US and Canada) and Moderna have announced the …

Latest content